報價延遲最少15分鐘:2026/04/21 20:01 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.62 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.14/-3.14
|
|
企業價值
698.62M
|
| 資產負債 |
|
每股賬面淨值
6.78
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
262.60M
|
|
每股收益
2.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to targetcertain harmful proteins causing oncology and neurology-related diseases. |
